*September 2020*

The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1 CHRYSALIS study that were presented during the 2020 ESMO Virtual Congress.
Amivantamab is a fully human bispecific antibody that targets EGFR and MET. The antibody has immune cell-directing activity, including antibody-dependent cell cytotoxicity, and demonstrated clinical activity in patients with primary and acquired EGFR resistance mutations. Lazertinib is a potent third-generation EGFR TKI that demonstrated activity in patients with activating EGFRmutations, T790M resistance mutations, and central nervous system (CNS) disease. With low rates of EGFR-related toxicity, such as rash and diarrhea, the safety profile of the agent supports its use in combination with other EGFR inhibitors. Read more.

Donate

Support EGFR

Latest Newsletter

Get Social: Twitter

Categories